Health Catalyst (NASDAQ:HCAT) Earns "Equal Weight" Rating from Stephens

Stephens reissued their equal weight rating on shares of Health Catalyst (NASDAQ:HCAT - Free Report) in a research report released on Thursday morning,Benzinga reports. Stephens currently has a $7.00 target price on the stock.

HCAT has been the topic of a number of other research reports. Canaccord Genuity Group dropped their target price on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 21st. Wells Fargo & Company cut their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a report on Tuesday, January 21st. Piper Sandler lowered their target price on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a report on Tuesday, February 11th. Citigroup cut their price target on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Finally, KeyCorp upgraded shares of Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.45.

Remove Ads

Health Catalyst Stock Down 1.5 %

Shares of HCAT traded down $0.07 on Thursday, reaching $4.60. The company's stock had a trading volume of 1,833,303 shares, compared to its average volume of 869,544. Health Catalyst has a twelve month low of $3.76 and a twelve month high of $9.24. The stock has a market capitalization of $279.90 million, a PE ratio of -3.41 and a beta of 1.34. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a fifty day moving average of $5.98 and a 200-day moving average of $7.24.

Insider Buying and Selling

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total value of $30,003.84. Following the completion of the sale, the chief operating officer now owns 86,044 shares of the company's stock, valued at approximately $495,613.44. This trade represents a 5.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the sale, the insider now directly owns 98,702 shares in the company, valued at approximately $777,771.76. This trade represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 80,110 shares of company stock valued at $596,993. 2.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently modified their holdings of the business. First Light Asset Management LLC boosted its holdings in Health Catalyst by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock worth $37,055,000 after buying an additional 944,631 shares during the period. Impax Asset Management Group plc lifted its position in shares of Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company's stock worth $19,442,000 after acquiring an additional 195,525 shares in the last quarter. Daventry Group LP boosted its holdings in shares of Health Catalyst by 3.8% in the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company's stock worth $17,742,000 after acquiring an additional 91,878 shares during the period. Primecap Management Co. CA grew its position in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company's stock valued at $19,572,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its stake in shares of Health Catalyst by 74.4% during the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after purchasing an additional 861,150 shares during the period. Hedge funds and other institutional investors own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.